Impact of HIV and Its Treatment on Reverse Cholesterol Transport

NCT00168233 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2012-01-20

No results posted yet for this study

Summary

To investigate the effect of treatment of HIV infection with highly active antiretroviral therapy on individual steps of reverse cholesterol transport, endothelial function and intima-media thickness in HIV patients.

Conditions

  • HIV Infections

Sponsors & Collaborators

  • National Health and Medical Research Council, Australia

    collaborator OTHER
  • The Alfred

    lead OTHER

Principal Investigators

  • Dmitri Sviridov, Dr · Baker Heart Research Institute, Commercial Road, Melbourne

  • Jennifer Hoy, A/Prof · Alfred Hospital, Melbourne, Vic 3004

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2010-09-30
Completion
2011-03-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00168233 on ClinicalTrials.gov